SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-030203
Filing Date
2024-02-09
Accepted
2024-02-09 16:56:01
Documents
18
Period of Report
2024-02-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d185041d8k.htm   iXBRL 8-K 30216
2 EX-1.1 d185041dex11.htm EX-1.1 215010
3 EX-4.1 d185041dex41.htm EX-4.1 64251
4 EX-5.1 d185041dex51.htm EX-5.1 20237
8 GRAPHIC g185041g19l86.jpg GRAPHIC 4684
  Complete submission text file 0001193125-24-030203.txt   543914

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20240206.xsd EX-101.SCH 2898
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20240206_lab.xml EX-101.LAB 17978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20240206_pre.xml EX-101.PRE 11290
19 EXTRACTED XBRL INSTANCE DOCUMENT d185041d8k_htm.xml XML 3646
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 24615844
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)